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ABSTRACT
Genetic Analysis of Smad2 gene in Hepatocellular Carcinoma
Alper Romano
M.S. in Molecular Biology and Genetics 
Supervisor: Dr. Cengiz Yakicier 
July 1998, 58 pages
Hepatocellular carcinoma is one of the most malignant cancers and is the 
most frequent one in some regions in the world. Although it is a multistage disease, 
its genetic composition is not well understood. TGF(3 is shown to be a strong 
inhibitor of cell growth and during hepatocellular carcinogenesis there is an escape 
from the anti-proliferative effect of TGF(3. Smad2 protein is the mediator of response 
to TGFP and its gene is mutated in several cancers. To clarify the role of Smad2 in 
TGFP signalling in hepatocellular carcinoma we performed single-strand- 
conformation-polymorphism (SSCP) analysis in five exons of Smad2 for 35 tumor 
samples and in C-terminal region for five hepatoma cell lines. Two alterations were 
found out of 35 samples and no abnormal expression or big deletions were observed 
in cell lines. Thus Smad2 might be involved at least a part of hepatocellular 
carcinomas.
Ill
ÖZET
Hepatoselüler karsinomlarda Smad2 geninin genetik analizi
Alper Romano
Moleküler Biyoloji ve Genetik Bölümü Yüksek Lisansı 
Tez Danışmanı: Dr. Cengiz Yakıcıer 
Temmuz 1998, 58 sayfa
Hepatoselüler karsinom en kötü huylu kanserlerden biri olup, dünyanın bazı 
yörelerinde en sık rastlanan kanser türüdür. Çok aşamalı bir hastalık 
olmasına rağmen genetik içeriği pek anlaşılamamıştır. TGF|3, karaciğer hücre 
büyümesinin güçlü bir engelleyicisi olup, hepatoselüler karsinom sırasında 
TGFP’nın anti-proliferatif etkisinden bir kaçış söz konusudur. Smad2, TGF(3 
sinyalinin hücre dışından hücre çekirdiğine taşınmasından sorumlu bir 
proteindir ve bu genin bazı kanserlerde mute olduğu gösterilmiştir. Smad2 
geninin hepatoselüler karsinomlardaki TGFp sinyalindeki rolünü açığa 
kavuşturmak için beş exon için 35 tümör örneğinde ve C-ucu bölgesi için beş 
hepatom hücre hattında (celi lines) SSCP analizi uyguladık. 35 örnekte iki 
değişiklik bulundu ve hücre hatlarında ifade bozukluğu ya da büyük 
delesyonlar gözlemlenmedi. Sonuç olarak, Smad2, hepatoselüler 
karsinomların en azından bir kısmında rol oynuyor olabilir.
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The liver is a large digestive gland where nutrients are processed. It comprises a 
mixture of cell types, although most prevelant cells are the epithelial liver cells , so 
called hepatocytes. Hepatocytes perform a broad range of metabolic and secretory 
tasks. Even though hepatocytes derive from gut epithelium, they have a different life­
style compared to other gut epithelial cells. Under normal physiological conditions, 
adult hepatocytes are non-dividing cells but they retain their capacity to proliferate. 
Proliferation is seen only either as a response to massive hepatocyte loss ( partial 
hepatectomy, hepatotoxic agent intake, acute and chronic hepatitis, cirrhosis) or as a 
result of loss of antiproliferative control ( hepatocellular carcinoma) (Ozturk 1994). 
Therefore, cell proliferation plays a key rol during tumorigenesis, as observed in the 
rat model (Grisham 1996).
1.1 Hepatocellular Carcinoma
1. INTRODUCTION
More than 80 percent of primary liver cancers are primary hepatocellular carcinoma 
(HCC) which derive from hepatocytes. It is the 7th most common cancer in males and 
males develop HCC 2-3 times more than women. HCC carries a poor prognosis, with 
survival times from diagnosis measured in months. Although surgical resection by 
partial or total hepatectomy is available, partial hepatectomy is associated with a very 
high recurrence rate ( 25 percent per year) (Isselbacher et al. 1991). HCC is the 4th 
most common cause of death from cancer, responsible for 300000 deaths each year.
While hepatitis B and hepatitis C viral infections are considered major etiological 
factors, poor nutrition, alcohol and cigarette consumption, food and water 
contaminants, natural plant toxicants and oral contraceptives may also play a role. The 
incidence of HCC is generally low in Western countries ( 1-7/100000 ) and high in 
South-east Asia and sub-Saharan Africa ( 25-75/100000) (Bosch and Munoz 1990).
1.1.1 Hepatic cirrhosis and fibrosis
The most frequent form of liver injury (hepatocyte destruction) occurs during chronic 
HBV and HCV infections. These infections cause decades of inflammation that ends 
up with fibrosis. Hepatic fibrosis is a response to liver injury by recruitment of 
inflammatory cells, activation of mesenchymal (stellate) cells and release of 
cytokines. An important feature of hepatic fibrosis is that it is a reversible 
accumulation of extracellular matrix in response to chronic injury in which nodules 
have not yet developed, whereas cirrhosis implies an irreversible process in which 
thick bands fully encircle the parenchyma, forming regenerating nodules (Burt 1993).
80% of HCC develop a cirrhotic liver, mostly due to chronic viral infections. 
Furthermore, about 38 percent of patients with HBV- associated cirrhosis had HCC 
at autopsy. It should be noted that although presence of cirrhosis increases the risk for 
HCC it is not a requirement (Craig et al. 1990).
1.1.2 HBV and HCV
HCV infection is a major risk factor for the development of HCC worldwide. Two 
facts are employed as evidence : 1) 50- 75 percent of HCC patients have anti-HCV or 
HCV RNA detectable in serum in southern Europe and Japan. 2) In patients with 
chronic HCV infection, progression can be noted from milder forms of hepatitis to 
cirrhosis, and eventually, to HCC. Unlike the HBV, HCV is not a DNA virus and 
doesn't become integrated into host genome. It is likely that HCV has an indirect 
effect by causing liver injury. After 20 years of infection, 6-8 percent of patients with 
chronic hepatitis C can be expected to have developed HCC (Di Bisceglie 1998).
Hepatitis B surface antigen is common in countries where HCC is also common. 
HBsAg carriers are 40-100 times higher at risk to develop HCC than the non-carriers. 
HBV is a DNA virus and after infection it becomes integrated into host genome. But 
the location of integration was shown to be random and probably has no effect on 
pathogenity. HBV doesn't possess any gene product with transforming activity. Its X 
gene product which acts as transcription factor both for the virus and the host genome, 
was demonstrated to bind to p53 and cause its inactivation. Thus, this can be a 
mechanism of tumour progression (Feitelson 1993, Ueda et al. 1995).
1.1.3 Aflatoxin
Aflatoxin is a myotoxin produced by some species of Aspargillus. In the regions were 
HCC is epidemic, aflatoxin is taken in as a food contaminant. It is the only etiological 
factor that was shown directly to cause p53 mutation. It targets the codon 249 of p53
genes, and impairs its activity. This mutation is a hotspot where aflatoxin exposure is 
high but low in other areas (Ozturk et al. 1991, Ozturk et al. 1994)
1.1.4 Genetics of HCC
Like many other cancer types HCC is a multistage disease while taking decades to 
develop it. But the genes which are inactivated during tumourigenesis are poorly 
identified.
It is known that overexpression and/or activation of cellular protooncogenes and 
deletion or inactivation of tumour suppressor genes occur during multi-step 
carcinogenesis through either point mutations, gene amplification, gene 
rearrangement, alteration in gene méthylation pattern, or a change in transcriptional 
regulation. These genes encode proteins of the cellular signal transduction system, 
which function to regulate gene expression, cellular growth and differentiation 
(Alberts et al. 1994).
1.1.4.1 Allelotyping studies
Different LOH studies revealed that some chromosome regions are commonly deleted 
in HCC and these regions might harbour one or more tumour suppressor genes. 
Previously LOH were reported on Ip, 4q, 5q, 6q, 8p, lOq, 1 Ip, 16p, 16q and 22q. An 
extensive allelotypic analysis of HCC let us identify new regions that were previously 
not detected (Nagai et al. 1997). The highest rates of LOH are shown in table 1.
Table 1 High Frequence of Loss of Heterozygosity (LOH) in HCC
Chr. Location LOH rate Candidate
(%) Genes
2q36-37 29%
4q35 40%
6q27 36% M6P/IGF2R
7pl5 30%
8p23 42%
13ql2-ql3 30-32% RB, BRCA2
16q23-q24 28%
17pl3 33% p53
Other regions which were shown also to be deleted for the first time are in table 2.
Table 2 Other chromosomal regions lost during MCC
Chr. Location LOH rate
(%)
Iq22-q23 20%
Iq42-q43 24%
7q33-q34 20%
8q23-q24 23%
9pl2-pl4 21%
9q34-qter 20%
14q32 23%
17q24 21%
1.1.4.2 Mutations
During HCC, candidate genes are not commonly inactivated. Most of the tumor 
suppressor genes are rarely mutated. Additionally, mutations in oncogenes are also not 
common ( table 3 ). Some alterations which change the expression or the activity of 
the protein have been observed in HCC (table 4).
Table 3: Mutations in tumoursuppressors and oncogenes
Genes LOH% Mutation References
P53 51% 30-55% Puisieux and Ozturk 1997
M6P/IGF2R 70% 25% De Souza et al. 1995
61% 55% Yamada et al. 1997
P16 4/26 germline Chaubert et al. 1997
%41 1/23 Bidenetal. 1997
yes 3/62 Kita et al. 1996
RB Rare Zhang X. et al. 1994
BRCA2 1/60 somatic Katagiri et al. 1996
2/60 germline
DLC-1 44% Yuanetal. 1998
PRLTS 2/48 Fujiwara et al. 1995
Ras Rare Shen and Ong 1996
1.1.4.3 Other alterations
Table 4: Alterations other than mutations in tumour suppressors and oncogenes 
in HCC
pl6 48% de novo meth. Chaubert et al. 1997
IGF2 20% overexpression Li et al. 1997
Uchida K. et al. 1997
CyclinDl 4/30 amplifications Zhang Y. J. et al. 1993
p53 inactivation by HBx Feitelson et al. 1993
1.2 Transforming growth factor P (TGFp)
1.2.1 Biological effects of TGFP
TGpp is a 25 kDa homodimeric peptide which is produced by nonparenchymal liver 
cells and secreted in a latent form. It appears to be an important cytokine both in 
normal and diseased liver. Because it is able to increase the levels of many 
extracellular proteins, it has been closely associated with the promotion of fibrosis and 
progression of cirrhosis. In normal human hepatocytes no TGPP messenger or protein 
is detectable. In cirrhotic livers although hepatocytes in nodules continue not to 
express TGpp, some cells in fibrous septa expressed it. In hepatocellular carcinomas, 
clusters of tumoural hepatocytes express large amounts of TGpp. Interestingly normal 
and cirrhotic liver cells express the TGFp receptors but they disappear in plasma 
membrane of tumour hepatocytes though they were in cytoplasm (Bedossa et al. 1995). 
The apparent paradox of how hepatocytes proliferate despite of production of 
elevated TGpp production by nonparenchymal cells is best clarified in a rat model. 
Accordingly, TGppi is expressed only in nonparenchymal cells, but TGpp receptors 
were expressed in both cell types. As the liver regeneration reach its peak, TGppi 
mRNA levels are elevated and there is a significant depression of TGpp receptor 
mRNA levels only in hepatocytes (Date et al. 1998).
Transforming growth factors (TGF-P) are potent inhibitors of proliferation of most 
cell types in culture and in vivo. However many tumorigenic cell lines have lost 
response to negative growth-regulatory effects of TGppi which is the most commonly
studied TGPp molecule. Thus, it has been thought that the understanding of the
8
molecular mechanism of the TGpp will reveal much about the tumorigenesis. 
Although many cell cycle proteins have been thought as potential targets of TGF|3 
such as cyclins, cyclin dependent kinases (Cdks) and Cdk inhibitors, it is not clear yet 
whether these targets are directly involved or the effect on these targets are simply a 
consequence of the TGppi induced growth arrest (Alexandrow and Harold 1995),
There has been conflicting results about the role of TGppi at early and late stages of 
carcinogenesis due to in vitro studies and different approaches. Accordingly, TGP(3l 
acts either as a tumour promoter or as a suppressor at early stages and either 
stimulates or suppresses the malignant progression during the later stages (Cui et al.
1996).
1.2.2 TGPP signalling pathway
Although transforming growth factor (3 (TGPP) was discovered as a peptide which 
stimulates the proliferation of rat kidney fibroblasts, it acts as a potent growth 
inhibitor of many normal cell types, including epithelial cells. It has been shown that 
it also induces cell differentiation and production of extracellular matrix proteins. 
TGP(3 belongs to a large superfamily of peptides which are structurally conserved 
throughout the evolution and includes members such as activins and bone 
morphogenic factors (BMPs) and they play important roles in differentiation and 
morphogenesis. TGPP has three different isoforms in humans (TGP(3l-3), encoded by 
different genes (Hoodless and Wrana 1994). It is secreted in a latent form from the 
cells and they become active by proteolysis in which IGF2R plays an important role 
(De Souza et al. 1995).
9
It has now been firmly established that most of these factors, including TGPP, signal 
through type I and II serine/threonine kinase receptors. Another receptor type called 
XPR-III is a proteoglycan with a short cytoplasmic domain. It is not required for the 
biological activity of TGppi and TGPPS but may have an accessory function for 
TGPP2. Type II and type I receptors are the main mediators of the TGPP signalling, 
they contain a cytoplasmic kinase domain and extracellular cystein-rich regions. In 
addition, type I receptor has a highly conserved cytoplasmic glycine- and serine-rich 
segment (GS domain). In the absence of ligand, XPR-I and XPR-II exist as homomers 
in the cell surface. In addition, XpR-II is constitutively phosphorylated by cellular 
kinases and by itself (Derynck 1994). Upon ligand binding by XPR-II, XPR-I which 
alone is not able to recognize free XGPP is recruited to form a heterotetrameric 
terniary complex. Then, XPR-I is phosphorylated by the kinase activity of XPR-II at 
its threonine and serine residues of GS domain. XPR-II itself is not a substrate of XPR- 
I and its phosphorylation is not altered as a consequence of ligand-induced complex 
formation. Thus, it can be concluded that XPR-I is downstream of XpR-II in the 
XGPp signalling and its kinase activity is essential for the phosphorylation of 
downstream substrates.( Wrana J. L. et al. 1994) (for figure see Appendix).
1.2.2.1 TGFP receptors
10
1.2.2.2 Smad proteins
The receptors for TGPP are quite specific and no other ligand has been shown capable 
of binding to them. But it is also clear that identification of downstream targets of 
TPR-I would reveal much information about the specific effects of TGFp. Smad 
proteins were identified as human homologues of Mad protein which mediates TGpp 
-like dpp signalling in Drosophila. At present, at least eight distinct Smad proteins 
were identified in humans. They are highly conserved at their amino-terminal MHl 
and carboxy-terminal MH2 domain among themselves and other vertebrates. These 
two domains are connected by a linker region which is less well conserved. It is 
extremely rich in serine and proline residues. Structural analysis showed that no 
known structural motifs exists in these genes. However sequence comparisons have 
revealed that Smadl, SmadS are highly homologous and form a group. Indeed 
functional and biochemical analysis have proved that they specifically carry BMP 
signalling while Smad2 and Smad3 form another group and are involved in 
activin/TGpp signalling. Thus, different signals recruit distinct Smads. These Smads 
are called receptor-regulated Smads. Smad4 is more distantly related to the other 
Smads and is a central protein for both pathways. Smad6 and Smad? thought to act as 
inhibitors of these signals (Kretzschmar and Massague 1998). It has been established 
that the MH2 domain of receptor-regulated Smads is responsible for most of its 
functions. The function of MHl domain is mere to inhibit the biological activities of 
MH2 domains by a direct physical interaction between MHl and MH2 domains 
(Kretzschmar et al. 1997). The carboxy-terminal of the receptor-regulated Smads 
contain a SS(V/M)S motif which is phosporylated by their type I receptors (Abdollah
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et al. 1997). This phosphorylation event was shown to be essential for the function of 
Smads. Upon phosphorylation, the inhibition of MHl domain is releaved and they 
form heteromeric complexes with Smad4 to enter into the nucleus (Macias-Silva et al. 
1996). Again, it is the MH2 domain of Smad2 and Smadl which interacts physically 
with Smad4. In nucleus these complexes are able to interact with other proteins and 
act as regulators of gene expression (Lagna et al. 1996).
As inhibitors of TGpp/BMP signalling, Smad6 and Smad7 constitute a distinct class 
of Smads. They lack the SSXS motif at their carboxy terminal. Smad7 is able to block 
the activation of target genes, induced by TGF(3, probably by association with TGFb 
receptor complexes (Hayashi et al. 1997, Nakao et al. 1997). Smad6 has also an 
inhibitory effect, but whether its function is specific for BMP signalling or it is a 
general inhibitor has yet to be clarified (Imamura et al. 1997).
Are the Smad proteins targets of other kinases and signalling pathways? The cellular 
signalling pathways are complex and dynamic processes. They may recruit the same 
substrates and have synergistic or antagonistic effects. Interestingly, Smadl is shown 
to be phosphorylated at serine residues in the linker region by Erk MAP kinases in 
vitro and in vivo. This phosphorylation inhibits the nuclear accumulation of Smadl. 
Thus Erk kinase pathway can have an antagonistic effect on BMP induced signalling 
(Kretzschmar et al. 1997). There is also evidence for a similar mechanism for Smad2 
(De Caestecker et al. 1998).
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1.2.2.3 Transcriptional activation by Smads
One of the first evidence came from the fact that when fused to GAL4 DNA-binding 
domain, C-terminals of Smadl, Smad2 and Smad4 are able to act as transcriptional 
activators (Liu et al. 1996). A study in Xenopus embryos have shown this hypothesis 
to be true also in vivo. In response to activin or TGF[3, a complex called activin- 
response factor (ARF) is formed, and binds to the promoter region of Mix2, an 
immediate-early activin response gene. This complex contains both FASTI, a winged- 
helix transcription factor and XSmad2. The MH2 domain of XSmad2 interacts with 
FASTI (Chen et al 1996). The third component of ARF is identified as Smad4 and 
both its MHl and MH2 domains are essential for the stimulation of Mix2 reporter, 
contributing to DNA-binding and transactivation functions respectively (Chen et al.
1997). A similar example is activation of Xenopus forehead gene directly by C- 
terminal of XSmad2 via defined regulatory regions (Howell and Hill 1997). The 
dissimilarity between these regulatory sequences can be best expained that either 
Smads interact with different transciption factors upon nucleus entry or there is dose- 
dependent action of activin. While these target genes are restricted to Xenopus, 
Smads regulate directly the TGFP inducible human type VII collagene gene 
expression (Vindevoghel et al. 1998).
A recent study (Moustakas and Kardassis 1998) have shown that in HepG2 hepatoma 
cell lines which are responsive to TGF|3 , Smad proteins are able to regulate and 
increase the hepatic activity of p21/WAFl expression. It is suggested that Smad3 and 
Smad4 probably exert this effect by functionally interacting with transcription factor
13
Spl rather than directly binding to DNA. Another study shows that Smad3 and Smad4 
are part of a nuclear complex that directly binds CAGA boxes in the promoter of 
PAI-1 upon TGPP induction. But Smad2 neither participates in it nor binds to these 
elements (Dennler et al. 1998).
1.3 TGFP Signalling and Cancer
The resistance to TGpp induced growth inhibition in tumours probably results from 
disruption of one of the components of TGpp signalling pathway. As the 
understanding of this pathway increased, several proteins shown to be mutated in 
various cancers and they became strong candidates of tumour suppressor genes.
1.3.1 M6P/IGF2 Receptor
M6P/IGP2 Receptor has distinct activities which are important for the regulation of 
different molecules such as mannose 6 phospate and IGP2 . IGP2 is a growth and 
survival factor which is degraded by this receptor. Interestingly, the inactive form of 
TGPp also binds to IGF2R and is activated by plasmin with the help of the receptor. 
Thus, inactivation of this receptor will have two effects. First, it will increase the level 
of IGF2. Second, it will decrease the active TGPP levels which may help the 
hepatocytes to escape from negative-growth effect of TGpp. Frequent loss of 
heterozygosity and mutations of IGF2R gene have been reported in HCC ( De Souza 
et al. 1995, Yamada et al. 1997).
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1.3.2 TGFP Receptors
Many cancer cell lines are known to acquire TGPP resistance. Inactivating mutations 
in TGpp receptor type II and type I, can be a cause for TGpp resistance in cancer. 
Mutations have been identified in TPR-II gene, in two head and neck squamous cell 
carcinoma (HNSCC) cell lines (Garrigue-Antar et al. 1995), in cutaneous T-Cell 
lymphoma cell lines (Knaus et al.l996), in colon and gastric cell lines (Vincent et al. 
1997) and in colon cancer cells with MSI (Markowitz et al. 1995). These mutations 
can reflect genetic changes aquired in culture rather than the real situation in primary 
cancers. Indeed, until now, XPR-II was shown to be mutated only in sporadic colon 
(Takenoshita et al. 1995) and endometrial (Lu et al. 1996) cancers with microsatellite 
instability (MSI), or in hereditary non-polyposis colorectal cancer (HNPCC) cases (Lu 
et al. 1996) and not in cancers of breast, pancreas and liver (Vincent et al. 1996). Thus 
TPR-II acts as a tumor suppressor mainly in cancers with MSI, although a very recent 
study indicates that a HNPCC patient without MSI has a germline mutation in TPR-II 
gene outside the (A) 10 tract (Lu et al. 1998).
1.3.3 Smads
1.3.3.1 Allelotyping studies
Even before the identification of Smad4, 18q loss was seen frequently in many tumour 
types. But many of these studies are quite confusing because of discrepancies on the 
percantage and the location of LOH in a tumour type. An extensive study on 12
15
tumour types concentrated on 18q21.1 using polymorphic markers near Smad4 and 
Smad2. Significant losses ( >20%) were observed in HNSCCs, melanomas, 
osteosarcomas, in breast, lung, hepatocellular, ovarian, pancreatic and prostatic 
cancers (Schutte et al. 1996).
1.3.3.2 Mutational analysis
Most cell lines, who are insensitive to TGF|3, express intact TGpp receptors in their 
cell surface (Vincent et al. 1996). Thus, Smad proteins as mediators of TGF(3 
signalling are candidate tumor suppressors. Smad4 was first identified as a candidate 
tumor suppressor gene involved in pancreatic cancer (Hahn et al. 1996). Later on, it 
was shown to be mutated frequently also in colorectal cancers (Thiagalingam et al. 
1996, Takagi et al. 1996), but infrequently in ovarian cancers (Schutte et al. 1996), in 
lung cancers (Nagatake et al. 1996), in gastric carcinomas (Powell et al. 1997) and 
recently in biliary tract carcinoma (Hahn et al. 1998). Smad2 mutations are observed 
only in colorectal (Riggins et al. 1997, Eppert et al. 1996) and in lung (Uchida et 
al.l997) cancers (Table 5). Recently germline mutations were found in Smad4 in 
families with juvenile polyposis syndrom (Howe et al. 1998).
Majority of the mutations are harboured within the carboxy terminal MH2 domain.
The crystal structure of C- terminal domain of Smad4 revealed that it forms a trimer
in crystal. Most of the missense mutations are in trimer-interface and disrupt the
homo-oligomerization. These mutation also prevented formation of heteromeric
complexes between Smad4 and Smad2. It can be concluded that homomerization of
Smad4 is prerequisite for heteromerization and signal transduction (Shi et al. 1997).
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A conserved Arginine residue in the N terminal of is shown to be mutated both in 
Smad4 and Smad2 . N-terminal of the Smads have an inhibitory effect on Smad 
function by interacting with its C-terminal. It was shown that these mutations increase 
the affinity of N-terminal on C-terminal and create an autoinhibitory effect. Such 
mutations abolish the function of phosphorylation and thus formation of heteromeric 
complexes ( Hata et al. 1997),
Table 5: Somatic mutations in Smad2 gene.
Mutation Codon Exon Tumour type Reference
Deletion 345-358 9 Colorectal RIGGINS et al.
CTT- CGT L440R 11 Colorectal
c c
c c
c c
EPPERT et al.
c c
c c
c c
CCT- CAT P445H 11
GAC-GAG D450E 11
CGC-TGC R133C 4
GAC-CAC D450H 11 Lung
c c
UCHIDA et al.
c cDeletion 434-436 11
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1.3.3.3 Knockout and Transgenic Mouse Models
Knockout mice for Smad4 die before day 7.5 of embryogenesis. The growth 
retardation, lack of gastrulation and impaired differentiation is similar to the 
phenotype of Bmp4 mutant embryos. Additionally, the anterior-posterior axis is also 
disrupted in rescued embryos. These data suggests that a central signalling molecule 
of TGPP related pathways, Smad4 is essential for embryogenesis (Sirard et al. 1998).
Similarly Smad2 mutant embryos demonstrated that Smad2 function is essential for 
the establishment of anterior-posterior polarity, and development of the primitive 
endoderm lineage. These mutants entirely lack embryonic germ layer tissues (Waldrip 
et al. 1998). Interestingly, TGF|3l-3 or activin deficient mice are normal at birth 
(Schull et al. 1992). This fact can be explained either by redundancy of these 
molecules or that Smad2 acts downstream of other yet unidentified ligands.
Mice which are transgenic for TGF-a under the MMTV promoter develop mammary 
tumours. In mice transgenic both for TGF-a and TGF-P there is resistance to 
mammary tumour formation, probably by reduction of epithelial mass (Pierce et al. 
1995)
A transgenic mouse model with keratinocyte-targeted expression of TGF^l suggests 
that TGFpi has biphasic effects during multistage carcinogenesis. At early tumor 
promotion stages of carcinogenesis, TGFpi acts as a growth inhibitor of kératinocytes 
and inhibits benign tumour outgrowth. At later stages the cells that were able to 
escape this inhibition through genetic alterations in TGFP signalling, have an elevated
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level of TGFßl which enhances their malignant conversion. The mouse model clearly 
shows that the TGFßl effects the malignant phenotype by altering the expression of 
extracellular matrix and cell adhesion molecules rather than by evasion of host 
immune surveillance, enhancement of angiogenesis or elevated apoptosis (Cui et al. 
1996).
Compound heterozygote mice , carrying both mutant Smad4 and APC genes were 
viable and they lost the wild-type allele in tumour tissue. Interestingly, the intestinal 
tumours progressed into a malignant phenotype at a much earlier stage than the Apc- 
knockout mice. Thus, Smad4 mutations are sufficient to bring the polyp adenomas 
induced by APC mutations , in a malignant stage without any other genetic changes. 
(Takaku et al. 1998).
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As discussed before, TGPP has a strong anti-proliferative effect on normal 
hepatocytes. Nevertheless, the malignant hepatocytes express TGF|3 and continue to 
proliferate. As observed in other cancers and some hepatoma cell lines escape from 
anti-proliferative effect of TGpp might be an important step during hepatocellular 
carcinogenesis.
Therefore, we think that TGP(3 signalling pathway is involved in hepatocellular 
carcinogenesis. Smad2 is a direct mediator of TGpp response and was shown to be 
mutated in several cancers. So we concentrate our efforts on the genetic alterations of 
Smad2 in liver cancers. Smad2 is a 467 aa protein coded by 11 exons and is located 
near Smad4 on 18q21.1 where LOH was observed in some cancers (Takenoshita et al
1998).
The aim of this study is to check whether the genetic abnormalities of Smad2 gene are 
involved in hepatocellular carcinoma.
2. AIM
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3. MATERIALS AND METHODS
3.1 Tumour Specimens and cell lines
Genomic DNA of 35 tumours were chosen from a collection as published in (Unsal et 
al. 1994). The patients were from South Africa(n=l 1), China (n=8), 
Mozambique(n=7), Japan (n=6), and Germany (n=3). 80 % percent of the samples are 
HBV positive and 20 % had p53 mutations. From the informative cases(n=20), 20% 
had cirrhosis (table 6).
Six hepatoma cell lines were used in this study are HepG2 (Aden et al. 1979), Hep3B 
(Aden et al. 1979), HuH7 (Nakabayashi et al. 1982), Mahlavu (Alexander et al. 1984), 
FOCUS (He et a l l 984) and PLC/PRF/5 (Alexander et al. 1976).
3.2 Solutions:
lOxTBE Buffer Solution 
108 g Tris 
55 g Boric acid
8.3 g EDTA
are dissolved in 1 It of deionized water until its pH is 8.3
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Table 6: Characteristics of tumour samples
IUM(JKS P53 HBV Sin;ul2 1 Stfitlc < arrliosis Metiislii.sis
T8 i SA-1.7 WT N
1
i Hiüly Ní> No
TI7,ÇSA'T) ! WT - N Lalo Yes Ycs
r is  (M) 249 Mul + N 1 Lalo Ni> No
I  WT - [ N ! Laic No No
T19 S^A T ) ! WT - N Lalo No No
121 (SA-T) I w f  {'.s-v) + N i I..aic Nt) Yes
121 (M) ' 249 Mul •T N 1 -au; Yes Ycs
T29 <;M) ! 249 Mul - N i barí y No Nt>
'П1 (SA-’i'i ! WT + N Laic Yes Ycs
'1M (SA-T) i WT + i1 1 \л\\с No Ycs
I WT ...._ + ..... ... [ 1.Л1С Yes Vos
1A7ÍM) + ! AU. Exil I..íUto Yes Ycs
T39 (SA-S) Wr ! -h K i r.alc i..........Yes No
T43 Î S A -T) 286-Sbp-<l(;l ' + N Late· No Nu Inior.
T47(M)..... Г 157 Mul I + ! N Lato No No
T49 (SA -6 ! WT i 1 ' A il. Ex K) I^ alo i No No
T5l (M) ' WT + 1 N Late ' No 1 _ Ycs
T53 (M) i WT I + ; N Late , Yes No
T73 (G) WT (Ex 7-9) i ■+· 1 N l.ato ! Yes
T80 (G) ! W'I' + i N ! No íníor. i Yes No init>r.
C2(C) I WT !
Í
+ 1 N No Inlor. i No íníor. i No lniv>r .
C3 (C) i WT !
I
1 ! N No Inlor, Nt) Inlor. ! Nolnior
C6 (C) I WT i ·+ ! N No liUoi. No íníor. No Inior.
07 (C> i WT I i+  i N i No Iníor. No íníor. ! .No Inior.
CIO(C) j 249 Mul Í 4· i N i Nt) íníor. No Iníor. No Inior.
C12 iC) j WT i +  i N 1 No Iníor. No Iníor. No Inior.
( : i 5 c c ) i WT j + N No inlor. No Iníor. No iniV)r
....... Ç23(C) j WT + N i No iníor. No Iníor. No in loi. j
JITÜ) w r + N ' No Jnlor. No Iníor. No inior.
J3T (J) i W'T (Hx 5-7) + N 1 No Iníor. No Iníor. Nt) Infor.
J4T (J) WT (Fix 7-9) -1- N : No Iníor. No Iníor. Nt) lnit)i.
m  (i) WT(Fîx7;9) - N 1 No lnh>r. No Inlor. Nt) Inior.
J9T(J) j WT (bx 7) - N ! No Inlor. No ínít)r. Ni.) Init)r.
л о т  (J) i W'T (Ex 7) : N 1 No Iníor. No Iníor. No hiior.
G5 (G) ; WTiHxS-7) N 1 No Iníor. No Iníor. No hilor.
The samples were from South Africa-Lesotho (SA-L), South Africa-Transkei (SA-T), 
South Africa-Swaziland (SA-S), South Africa-Caucasian population (SA-C), from 
Mozambique (M), Germany (G), Japan (J) and China (C).
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SSCP Loading Buffer Solution 
95 % Formamide 
0.04 % Bromphenol blue 
0.04 % Xylene Cyanol 
lOmM NaOH
6 X Loading Buffer Solution
30 % Glycerol
0.04 % Bromphenolblue
0.04 % Xylene Cyanol
AdH20
Agarose Gel Solution for PCR 
30 ml lx  TBE 
0.6 g Agarose
heated in microwave for 1 min. and added 1 ml of EtBr
Polyacrylamide Gel Solution for SSCP 
the stock solution is 50 %
49.5 g Acrylamide 
0.5 g Bisacrylamide 
Add ddHaOto 100 ml
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3.3 Expression of cell lines
3.3.1 PCR
Primers: The forward (F) and reverse (R) primers for the amplification of Smad2 
coding region are as follows (Riggins et al.) :
TC 104 (F ): 5' GG A TCC T AA TAC GAC TC A CTA TAG GG A G AC CAC CAT 
GGG TAA GAA CAT GTC GTC CAT C 3'
TC 103 (R ): 5' TTT CCA TGG GAC TTG ATT GG 3'
TC 104 (F) includes signals for transcription and translation
Polymerase Chain Reaction (PCR) conditions:
Reaction mixture: for each exon the PCR reaction was performed in 25 ml of mixture 
containing:
1 X Buffer 
1.5mMMgCl2 
0.8 mM dNTP mix 
20 pmol F primer 
20 pmol R primer 
50 ng DNA 
1 u Taq polymerase 
A H2O
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PCR conditions for amplification consisted of a 3-min dénaturation step at 95°C, 
followed by 35 cycles of 40 sec at 95°C, 40 sec at 56° and 90 sec at 72°C. After 35 
cycles a last step at 72°C for 7 min was added.
3.3.2 Agarose gel electrophoresis
5 ml of PCR product was mixed with 1 ml of 6 x loading buffer and loaded into 1.5 % 
agarose gel electrophoresis. They were run 80V for 40 min and then visualised under 
UV light.
3.4 Single-Strand Conformation Polymorphism (SSCP) Analysis
3.4.1 PCR conditions:
Primers: Intronic or partly intronic primers were designed by myself. The exact 
positions of the primers can be found in Appendix A. The forward(F) and reverse (R) 
primers for the amplification of each exon are as follows:
exon 4 : F: 5' TCTGATAGTGGTAAGGGTTT 3'
R: 5' GTCTCTTGATGGTCGTCTC 3'
exon 8 : F: 5' CAGTTACTTACTCAGAACCT 3'
R: 5' GCCTACATTATGAGTATACAG 3'
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exon 9: F: 5 'CCAAAGTCACACTGAAATAG 3
R: 5' AGCAAGTTGACATGATAGG
exon 10: F: 5' GCATGCTCATATTCTAAAAC 3'
R: 5' ACTGTGGAAATTTAAGAACC 3'
exon 11: F: 5' GCCTGTGGACTTGAATTTCAT 3'
R: 5' GGACTTGATTGGTGAAGCTTT 3'
C-term : F: 5' CAGGGTTTTGAAGCCGTCTA 3'
R: 5' CTTGAGCAACGCACTGAAGG 3'
Polymerase Chain Reaction (PCR) conditions:
Reaction mixture: for each exon the PCR reaction was performed in 25 ml of mixture 
containing:
1 X PCR Buffer
1.5 mM MgC12 
0.04 mM dNTP mix 
[33P] 0.5 |iCi dCTP 
20 pmol F primer 
20 pmol R primer 
50 ng DNA 
1 u Taq polymerase 
A H2O
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Reaction conditions: the reaction condition is the same for each exon except the 
anneling temparature (Ta). The Ta for each exon is as follows:
exon 4: 56°C
exon 10: 50°C
exon 8: 53°C
exon 11: 56°C
exon 9: 57°C
C-term: 60°C
PCR conditions for amplification consisted of a 3-min dénaturation step at 95°C, 
followed by 30 cycles of 30 sec at 95°C, 30 sec at Ta and 30 sec at 72°C. After 30 
cycles an additional step at 72°C for 5 min was performed.
3.4.2 Polyacrylamide gel electrophoresis:
The mixture contains:
I xTBE 
10 % Glycerol
20 % polyacrylamide gel solution 
add ddH2 0 to 100 ml
After mixed precisely and degased, 400 ml of 10% Ammonium persulfate (APS) and 
40 ml of Temed is added for a mixture volume of 100 ml. This solution is poured into 
gel apparatus and left for polymerization for 2 hours.
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SS CP reaction:
Mixture:
2 ml of PCR product was mixed with 8ml of SSCP loading buffer in an Eppendorf ® 
tube.
Dénaturation:
The tubes were denatured at 95°C for 2 min and then put immediatly into ice. 
Loading:
The samples were loaded into an electrophoresis apparatus and electrophoresed at 
4°C , at constant 45 W for 14 hours.
3.4.3 Exposure and development
Then the gel was dried on a 3M Wattman® paper and exposed to X-ray film for 3 
days. The exposed film was developed in developer machine.
3.4.4 Automated sequencing
The sequencing reactions were performed and analysed in ABI Prism 377 Sequencer, 
using the same primer as used for SSCP analysis.
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4. RESULTS
4.1 Smad2 expression in hepatoma cell lines
Xrt>“O
OK)
<
G OS
55
<1
oosC/) n
Smad2
iSiiiSiiiipi»
B»aipillSE:»£
i:.|(;;ii. :-..’t.;,j,
"' "  ‘  ' ■ .  ‘  li' ' i i '  ’%> > ^ '
Figure 1: Expression of hepatoma cell lines
Smad2 expression was not exactly known in the hepatoma cell lines. The whole 
coding region of six hepatoma cell lines are amplified by PCR (conditions described 
above). Single band was observed with expected size for all cell lines tested. All the 
six cell lines express Smad2. There are no large deletions in any of the cell lines. 
Although four of them had similar amounts of amplified products, a nested PCR from 
these products still shows that Hep3B and Huh? are less amplifyible (Figure 1).
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4.2 SSCP analysis of hepatoma cell lines
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Figure 2; SSCP analysis of Smad2(C-term) Figure 3; SSCP analysis of
for hepatoma cell lines in 10% Acrylamide gel wildtype and mutant p53
SSCP analysis is performed for a part of the conserved C-terminal domain of Smad2 
in five hepatoma cell lines. The upper and lower bands correspond to each single- 
stranded DNA of the amplified region. No different migration pattern (eg. no shifted
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bands) were observed (Figure 2). SSCP analysis for exon 7 of wildtype and mutant 
(p53248 and p53249 ) p53 genes are used as a control for the efficiency of SSCP 
conditions. Both mutants had a distinct migration pattern from the wild-type exon of 
the gene.
4.3 Sequencing analysis of hepatoma cell lines.
As to confirm the SSCP results, the PCR products of Smad2 (C-term) was 
sequenced. No alteration was detectable by sequencing data, confirming the SSCP 
results in Figure 1.
4.4 SSCP analysis of tumour samples.
Exons 4,8,9,10 and 11 of Smad2 gene were analysed by SSCP analysis in 35 samples. 
The results gave us three distinct bands, one far below of the g e l, and the other two 
in upper side of the gel relatively. The intensity of the lowest band was higher, and 
due to its migration pattern and intensity this band corresponds to the double-stranded 
product. The two upper ones migrate according to their confirmation and they 
correspond to the single strands (Figure 4)
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Figure 4: SSCP results of normal migrating bands (exon9)
No alterated bands were observed for any sample of exon 4 , exon 8 and exon 9. 
However an alteration was found both for exon 10 and exon 11.
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Figure 5: Alteration in T49
Tumour sample T49 showed a different migration pattern from the other tumour 
samples. Its both single strands migrated differentially from the others. (Figure 5). The 
band corresponding to the double-stranded product had a lower migration than the 
other double-strands.
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Figure 6: Alteration in T37
Tumour sample T37 showed also a different migration in its exon 11.
The less intense bands between two single strands (the most upper and lower bands) 
are either artifacts or phantom bands which are observed in many SSCP studies. They 
appear in each sample tested. Even the more intense bands like T39 or T47 had not 
such a shifted band below the lower single-strand (Figure 5 ).
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5. DISCUSSION
Members of TGF-P superfamily have very important effects on cell proliferation, 
differentiation, organ development and morphogenesis. TGF-P 1 itself is involved 
during embryogenesis and differentiation. It is known to be a potent inhibitor of most 
of the normal cells, mostly of epithelial cells. However, during tumourigenesis the 
malignant cells continue to proliferate although the TGFP levels in these tissues 
increase. It is even suggested that TGFpi is a enhancer of malignancy in 
carcinogenesis (Cui et al. 1996).
This paradox can be best explained that the cancer cells acquire mutations which 
enable them to escape from negative growth effect of TGFp. The last three years gave 
us many evidences that this might be true for many types of cancer. With the 
identification of TGFP receptors, especially one of them, TPR-II was shown to be 
mutated or inactivated. But, unfortunately these mutation were only observed in 
cancers with microsatellite instability, such as HNPCC and gastric cancers where a 
(A) 10 TpR-II is the target (Vincent et al. 1997). We can even suggest logically; as 
they are the only known receptors for TGFp, the effect of TGFP as an enhancer of 
malignancy can be accomplished if they remain intact. Smad2, 3 and 4 proteins are 
shown to be the sole mediators of TGFP until today. Together with the other Smads 
they have highly conserved amino- and carboxy-terminal domains. The C-terminal 
domain was shown to mediate the activity of TGFP both in invertebrates and in 
vertebrates, including mammalians ( Kretzschmar and Massague 1998 ). Smad4
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became the focus of cancer research when it was shown highly mutated in pancreatic 
cancers. It is located near to in 18q21.1 a region which shows a high rate of LOH in 
some cancer types ( Schutte et al. 1996 ). DCC gene which was thought to be the 
main target of inactivation in this region, is not considered as a tumour suppressor 
anymore. Interestingly, Smad2 ,the main partner of DPC4 in TGpp pathway, is also 
located very near to DPC4. They are inactivated in some cancer types (Riggins et al. 
1996, Eppert et al. 1996, Uchida et al. 1997). It is clear that such an inactivation will 
abolish the effects of TGpp. It is demonstrated that they are essential for the 
signalling.
It was long known that both during fibrosis, cirrhosis and during hepatocellular 
carcinoma there is an increase in TGpp levels, although the source of the production 
is still an unsolved question (Bedossa et al. 1995). Although there is one report 
showing microsatellite instability in hepatocellular carcinoma, the target gene 
mutations like XPR-II have not been studied (Salvucci et al. 1996). Purthermore, it 
was shown that they are intact and expressed (Vincent et al. 1996). Some has 
suggested that the receptors can be downregulated during tumourigenesis, but there is 
not enough evidence for it (Sue et al. 1995). Therefore, TGpp related Smads are 
potential targets of inactivation as the hepatocytes escape from inhibitory effect of 
TGPp.
The expression of Smad2 in liver cell lines were not clear and was not studied 
previously. The amplification of Smad2 cDNA in all six hepatoma cell lines clearly 
reveales that Smad2 is expressed in them, including Mahlavu cell line which is
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unresponsive to TGFpl (Ito et al. 1990). We have observed lesser amount of 
amplification for some cell lines. Studies have to be done in order to clarify Smad2 
protein expression in these cell lines. In addition, the SSCP analysis of the most 
conserved C-terminal region (codons 400-464) from cDNA have demonstrated that 
there is no alteration in this region of these cell lines. Automatic sequencing data of 
this region of five cell lines, including Mahlavu confirmed this information.
To detect the significance of Smad2 mutations in liver cancer, we performed SSCP 
analysis for five exons of Smad2 gene. The four exons cover all the conserved 
carboxy-terminal region (MH2 domain). This region alone is shown to be sufficient to 
mediate the TGFp signalling. Furthermore, all the mutations that are found until 
today, except one, are located in this domain. In structural analysis, these mutations 
are shown to impair the homomerization and heteromerization which are essential for 
transcriptional activity. Other developmental mutations of invertebrates are also 
located here. The other mutation is found in exon 4, in conserved N-terminal which is 
thought to have a negative-regulatory effect on C-terminus. Therefore, we chose this 
exon as the fifth exon for SSCP analysis.
SSCP analysis is more frequently used than the other mutation detection methods like 
hetero-duplex analysis or DGGE. It is an established technique and shown to detect 
about 80% of the actual mutations. All the mutational analysis of Smad genes on 
gene level are carried out by this technique. Furthermore, the shifted single strands 
give us an advantage to isolate them from the gel, and sequence them after 
amplification which is difficult for the heteroduplex technique because the
heteroduplexes contain normal and mutated strands. Additionally, Smad mutations are
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mainly missense mutations for which SSCP is shown to be powerful. Smad2 exons 
are small exons ideal for SSCP analysis which has the highest resolution between 100- 
250 base pairs.
SSCP analysis of two patients have shown to have alterations. Interestingly these 
belong to the last two exons of Smad2 in which 90 % of the mutations are located. 
One sample was from Mozambique (T37) and the other one (T49) from South Africa. 
It looks like that no correlation exists between their p53 status because one patient has 
p53 249 mutation whereas the other one has an intact p53. Both were infected by 
HBV. We used intronic primers to amplify genomic DNA of the patients. Therefore 
there is a chance that these alterations are mere polymorphisms in the introns. There is 
also a probability that these mutations are polymorphisms in the coding regions which 
seem highly improbable because according to the data published until now, there is 
no polymorphism in this region. One of the alteration had a lower shift in its 
doublestrand band which raises the question whether it can be a small deletion. For 
the other alteration (T37), when the sample which derived from non-tumour tissue 
was analysed by SSCP , it had a similar abnormal migration pattern like T37. So we 
may conclude that it is either a polymorphism or a germline mutation.
This is the first study showing a Smad2 alteration in liver cancer. It can be speculated 
that even though mutations of Smad2 and/or Smad4 (MS thesis of Burcu Irmak) are 
not frequent, this can be considered first study showing mutations of TGpp pathway 
in HCC.
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As future perspectives, the mRNA level of Smad2 in different hepatoma cell lines 
should be confirmed by using the expression level of a house-keeping gene as an 
internal control. Naturally, the protein expression levels of Smad2 also should be 
checked in cell lines , to have a final conclusion. The molecular cause for the altered 
bands have to be determined by sequencing analysis to find out the exact nature of the 
shift.
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SMAD2 gene C-term cDNA
PCR size: 198 bp 
Primers : TC 147-148 
Accession: AF027964
1197 1394
198 bp
SMAD2 gene EXON 4
Exon size: 204 bp 
PCR size: 189 bp 
Primers : GA 325-326 
Accession: U78728
317 520
* Mutation at codon 133
SMAD2 gene EXON 8
Exon size: 213 bp 
PCR size: 269 bp 
Primers : GA 437-438 
Accession: U78731
785 997 + 56
intron 8
138 bp 
■ 260 bp
SMAD2 gene EXON 9
Exon size: 138 bp 
PCR size: 242 bp 
Primers : GA 370-371 
Accession: U78732
998 1135 + 44
intron 8 intron 9
138 bp 
242 bp
SMAD2 gene EXON 10
Exon size: 145 bp 
PCR size: 275 bp 
Primers : GA 435-436 
Accession: U78732
1136 1280 + 37
intron 9
- 9 3 145 bp 
275 bp —
SMAD2 gene EXON 11
Exon size: 124 bp 
PCR size: 192 bp 
Primers : GA 368-369 
Accession: U78733
1281 1404 + 19
intron 10
- 49 124 bp 
192 bp —
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RISM
17«3B 148
3B 148 
Lane 17
Signal G:842 A:1394 T;1039 C:701 
DT47oAc(A Set-Any Primer}
SN 569
Points 840 to 2368 Base 1: 840
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